Compare 10X Genomics Inc (TXG) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Wendys Co — how do they compare? 10X Genomics Inc trades at $79 (market cap $10.07B), while Wendys Co trades at $6.22 (market cap $1.19B). The key difference: 10X Genomics Inc is far larger — about 8.5× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Wendys Co for 77 Days on average.
| TXG | WEN | |
|---|---|---|
Market Cap | $10.07B | $1.19B |
Volume | 5,657,286 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $97.74 | $9.33 |
52-Week Low | $11.48 | $6.10 |
Typical Hold Time | 92 Days | 77 Days |
Enterprise Value | $9.59B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Wendy's stock (WEN) trades at $6.11, down 0.81% recently, with a bearish technical signal and oversold RSI indicators. The company shows mixed fundamentals: it has beaten earnings estimates for three consecutive quarters but faces declining net income margins and high debt levels. Recent news highlights challenges, including a major franchisee bankruptcy and same-store sales declines, contributing to negative sentiment.
The outlook for WEN is cautious. While its low P/E ratio of 9.25 and consistent earnings beats offer value, risks from franchisee instability, competitive pressures, and declining profitability weigh on growth. Analyst consensus is a 'Hold' with a $7.58 price target, suggesting limited upside amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
